CCDC3 Antibody

What is CCDC3 and why is it important for research?

CCDC3, also known as fat/vessel-derived secretory protein (favine), is a secreted protein with a canonical length of 270 amino acid residues and a mass of approximately 30.7 kDa in humans. It has up to two different isoforms reported and is primarily expressed in umbilical vein endothelial cells (HUVEC) with lower expression levels in aortic smooth muscle cells (HASMC) . CCDC3 has been identified as an important regulator of gene expression and lipid metabolism . Recent research has shown that CCDC3 plays a significant role in epithelial ovarian cancer (EOC) tumorigenesis, with the omentum being a unique metastatic site for this aggressive disease . Understanding CCDC3 biology has implications for cancer research, particularly regarding adipose tissue-tumor interactions.

What detection methods are available for CCDC3 antibodies?

CCDC3 antibodies can be utilized in several detection methods:

The selection of detection method depends on your research question. Western blotting is preferred for basic expression studies, while ELISA offers superior quantitative capacity with detection ranges of 31.25-2000 pg/ml for human CCDC3 . For tissue distribution studies, immunohistochemistry provides spatial context for expression patterns.

What are the key considerations for sample preparation when using CCDC3 antibodies?

When preparing samples for CCDC3 detection, researchers should consider that CCDC3 is a secreted glycoprotein. For cell culture studies, both cellular lysates and conditioned media should be analyzed, as significant amounts of the protein may be present in the media. For lysate preparation, RIPA buffer has been successfully used in published protocols . Protein concentration should be quantified using methods such as the DC™ protein assay, and equal amounts loaded for comparative analyses . Post-translational modifications, particularly glycosylation, may affect antibody binding, so researchers should be aware of potential variability in detection efficiency between different sample types . For nuclear protein studies, such as when investigating potential interactions with transcription factors like β-catenin, specialized nuclear protein extraction kits have been employed successfully .

How can CCDC3 antibodies be used to investigate its role in cancer progression?

CCDC3 antibodies serve as critical tools for investigating this protein's role in cancer progression through multiple approaches:

• Expression correlation studies: Anti-CCDC3 antibodies can be used in western blotting to correlate CCDC3 expression with cancer progression markers. Research has shown that CCDC3 may influence epithelial-to-mesenchymal transition (EMT), as evidenced by changes in markers like E-cadherin, N-cadherin, vimentin, and fibronectin when CCDC3 levels are altered .

• Signaling pathway investigations: Investigators have used CCDC3 antibodies to explore its impact on the Wnt/β-catenin pathway by examining nuclear translocation of β-catenin and expression of downstream targets like c-myc and cyclin D1 .

• Prognostic significance assessment: Kaplan-Meier survival analysis incorporating CCDC3 expression data (determined via antibody-based methods) can reveal correlations with patient outcomes in cancers like EOC .

For mechanistic studies, combining antibody-based detection of CCDC3 with functional assays (invasion, migration) provides comprehensive insight into how this protein affects tumor cell behavior . Furthermore, co-expression analyses can identify genes with expression patterns similar to CCDC3 (correlation coefficient >0.3), potentially revealing functional relationships that merit further investigation .

What are the challenges in detecting different CCDC3 isoforms, and how can they be addressed?

Detection of different CCDC3 isoforms presents several technical challenges:

• Size resolution: With up to two reported isoforms in humans , researchers must ensure their gel electrophoresis conditions can adequately resolve these variants, which may have subtle size differences.

• Antibody specificity: Not all commercially available antibodies can differentiate between isoforms. To address this limitation:

  • Select antibodies specifically validated for isoform detection

  • Use antibodies targeting regions unique to specific isoforms

  • Employ complementary techniques like mass spectrometry for isoform validation

• Post-translational modifications: As CCDC3 undergoes glycosylation , this can affect apparent molecular weight and antibody binding. Researchers can address this by:

  • Using deglycosylation enzymes before Western blotting to eliminate glycosylation-related heterogeneity

  • Including glycosylation inhibitors in cell culture experiments to assess whether any observed size differences are due to variable glycosylation or true isoform differences

A methodological approach combining isoform-specific RT-PCR with Western blotting using antibodies targeting distinct regions can help comprehensively characterize CCDC3 isoform expression in experimental systems.

How can CCDC3 antibodies be integrated into studies of tumor-adipose tissue interactions?

CCDC3 antibodies are valuable tools for investigating tumor-adipose tissue interactions, particularly relevant to cancers with known adipose tissue tropism like epithelial ovarian cancer:

• Co-culture systems: In experiments where cancer cells are co-cultured with adipocytes, CCDC3 antibodies can quantify secreted CCDC3 in conditioned media using ELISA methods . This approach can determine whether adipocyte-derived CCDC3 influences cancer cell behavior.

• Immunohistochemical analysis of tumor-adipose interfaces: Using CCDC3 antibodies for tissue staining can reveal expression patterns at the interface between tumors and adjacent adipose tissue, providing spatial context for potential paracrine interactions.

• Neutralization experiments: Function-blocking antibodies against CCDC3 can be employed in co-culture systems to determine whether CCDC3 is necessary for observed effects of adipocytes on cancer cells.

• Tumor microenvironment studies: Since CCDC3 expression correlates with tumor-infiltrating immune cells , dual immunostaining with CCDC3 antibodies and immune cell markers can elucidate potential immunomodulatory functions of this protein in the tumor microenvironment.

A comprehensive approach would combine these methods with functional assays to determine whether adipocyte-derived CCDC3 promotes tumorigenesis through direct effects on cancer cells or by modulating the tumor microenvironment.

What are the optimal protocols for Western blot detection of CCDC3?

For optimal Western blot detection of CCDC3, researchers should follow these methodological guidelines:

• Sample preparation:

  • Cell lysis with RIPA buffer has been validated in published research

  • For nuclear protein analysis (e.g., when studying β-catenin interactions), specialized nuclear protein extraction kits are recommended

  • Protein concentration determination using the DC™ protein assay ensures equal loading

• Gel electrophoresis and transfer:

  • SDS-PAGE followed by transfer to polyvinylidene difluoride (PVDF) membranes has proven effective

  • Given CCDC3's molecular weight of ~30.7 kDa, 10-12% acrylamide gels provide optimal resolution

• Antibody incubation:

  • Primary antibodies specific to CCDC3 are commercially available from multiple vendors

  • Blocking with 5% non-fat milk or BSA for 1 hour at room temperature minimizes background

  • Overnight primary antibody incubation at 4°C typically yields optimal signal-to-noise ratio

• Detection:

  • HRP-conjugated secondary antibodies with chemiluminescent substrate provide sensitive detection

  • Imaging using systems like ChemiDocTMXRS+ scanner has been successfully employed in published protocols

For challenging samples or when detecting low abundance CCDC3, signal amplification methods such as biotin-streptavidin systems may improve sensitivity, similar to approaches used in ELISA detection of CCDC3 .

What controls should be included when validating CCDC3 antibody specificity?

Rigorous validation of CCDC3 antibody specificity requires several controls:

• Positive controls:

  • Cell lines with confirmed CCDC3 expression (e.g., HUVECs)

  • Recombinant CCDC3 protein as a size reference

  • Tissues known to express CCDC3 (adipose tissue, especially omental)

• Negative controls:

  • Cell lines with minimal CCDC3 expression

  • CCDC3 knockdown samples (siRNA or shRNA treated)

  • Secondary antibody-only controls to assess non-specific binding

• Specificity controls:

  • Pre-adsorption with recombinant CCDC3 protein should abolish specific signals

  • Multiple antibodies targeting different CCDC3 epitopes should show consistent detection patterns

  • Mass spectrometry confirmation of detected bands provides gold-standard validation

• Cross-reactivity assessment:

  • Testing across species if working with non-human models (CCDC3 orthologs have been reported in mouse, rat, bovine, frog, zebrafish, chimpanzee and chicken)

  • Testing related proteins with coiled-coil domains to exclude cross-reactivity

Documentation of these validation steps is essential for establishing confidence in experimental results and should be included in materials and methods sections of publications.

How should ELISA assays for CCDC3 be optimized for different sample types?

ELISA optimization for CCDC3 detection varies by sample type:

• Serum and plasma samples:

  • EDTA or citrate plasma has been validated for CCDC3 ELISA kits

  • Sample dilution optimization is crucial as CCDC3 concentrations vary between healthy and pathological conditions

  • Standard curves should range from 31.25-2000 pg/ml with detection sensitivity around 18.75 pg/ml

• Cell culture supernatants:

  • Collection timing is critical as CCDC3 is secreted over time

  • Serum-free conditions eliminate interference from serum proteins, but may alter cellular CCDC3 production

  • Concentration of dilute samples may be necessary for detection of low abundance CCDC3

• Tissue and cell lysates:

  • Extraction buffer composition significantly impacts CCDC3 recovery

  • RIPA buffer with protease inhibitors is recommended

  • Sample clarification by high-speed centrifugation minimizes particulate interference

Common optimization parameters include:

• Antibody concentrations (capture and detection)

• Incubation times and temperatures

• Blocking reagents

• Wash stringency

Double-antibody sandwich ELISA methods have demonstrated high specificity for CCDC3, with minimal cross-reactivity with other analogues . For maximum sensitivity, biotinylated detection antibodies coupled with streptavidin-HRP systems are recommended .

How can researchers address variability in CCDC3 detection across different experimental systems?

Variability in CCDC3 detection can stem from multiple sources that researchers should systematically address:

• Biological variability:

  • CCDC3 expression varies by tissue type, with higher expression in endothelial cells compared to smooth muscle cells

  • Expression may be influenced by experimental conditions (confluency, passage number, culture media)

  • Document and standardize these variables across experiments

• Technical factors:

  • Antibody lot variation: Use the same antibody lot when possible, or validate new lots against previous standards

  • Sample processing differences: Standardize protocols for sample collection, storage, and preparation

  • Detection system sensitivity: Calibrate detection systems regularly and include internal standards

• Post-translational modifications:

  • CCDC3 undergoes glycosylation which may vary between cell types and conditions

  • This can affect antibody binding efficiency and apparent molecular weight

  • Consider deglycosylation treatments to normalize detection if glycosylation is not the focus of study

• Methodological approach:

  • Use multiple detection methods (Western blot, ELISA, immunostaining) to cross-validate findings

  • Quantify CCDC3 at both protein and mRNA levels to identify potential post-transcriptional regulation

  • Include recombinant CCDC3 standards across experiments for normalization

Statistical analysis should account for this variability, with sufficient biological and technical replicates to establish confidence in observed differences between experimental conditions.

What are potential pitfalls in correlating CCDC3 expression with cancer progression markers?

When correlating CCDC3 expression with cancer progression markers, researchers should be aware of several potential pitfalls:

• Causality versus correlation:

  • Association between CCDC3 and EMT markers (E-cadherin, N-cadherin, vimentin) does not necessarily indicate a causal relationship

  • Functional studies (overexpression, knockdown) are needed to establish causality

• Heterogeneity considerations:

  • Tumor heterogeneity may result in variable CCDC3 expression within a single tumor

  • Sampling strategy must account for this heterogeneity to avoid biased results

  • Single-cell analyses may reveal subpopulations with distinct CCDC3 expression patterns

• Contextual dependencies:

  • CCDC3's impact may vary based on tumor microenvironment factors

  • Co-expression analyses have shown that CCDC3 correlates with specific gene expression patterns

  • Consider analyzing CCDC3 in the context of these co-expressed genes rather than in isolation

• Technical limitations:

  • Different antibodies or detection methods may yield varying results

  • Standardization of quantification methods is essential for reliable comparisons

  • Establish clear thresholds for "high" versus "low" expression based on objective criteria

• Multivariate analysis:

  • CCDC3's relationship with cancer progression should be evaluated in multivariate models

  • Include established prognostic factors to determine whether CCDC3 provides independent prognostic information

  • Kaplan-Meier survival analysis incorporating CCDC3 expression can provide valuable prognostic insights

How should researchers interpret discrepancies between CCDC3 mRNA and protein expression levels?

Discrepancies between CCDC3 mRNA and protein levels are not uncommon and may provide valuable biological insights. Researchers should consider several factors when interpreting such discrepancies:

• Post-transcriptional regulation:

  • microRNA regulation may selectively suppress translation of CCDC3 mRNA

  • mRNA stability differences can lead to divergent steady-state levels

  • RNA-binding proteins may affect translation efficiency

• Post-translational regulation:

  • Protein stability and half-life affect steady-state protein levels

  • Secretion rates impact intracellular CCDC3 detection (remember CCDC3 is a secreted protein)

  • Compartmentalization may sequester protein to specific cellular locations

• Technical considerations:

  • Antibody affinity and specificity affect protein detection sensitivity

  • RT-qPCR primer efficiency influences mRNA quantification

  • Sample processing may differentially affect RNA versus protein preservation

• Biological relevance:

  • Temporal dynamics: Protein levels often lag behind mRNA changes

  • Functional thresholds: Protein may need to reach certain levels for biological effect

  • Feedback regulation: Protein function may influence its own transcription

A systematic approach to investigating these discrepancies includes:

• Time-course experiments to capture temporal relationships

• Pulse-chase studies to determine protein half-life

• Analysis of both cellular and secreted CCDC3 pools

• Investigation of potential regulatory mechanisms through bioinformatic prediction and experimental validation

Discrepancies themselves may be biologically informative, potentially revealing novel regulatory mechanisms controlling CCDC3 expression in different contexts.

How might CCDC3 antibodies contribute to understanding its role in immune cell infiltration?

CCDC3 has been linked to tumor-infiltrating immune cells through correlation analyses , suggesting potential immunomodulatory functions that could be further explored using antibody-based approaches:

• Multiplex immunohistochemistry/immunofluorescence:

  • CCDC3 antibodies used in conjunction with immune cell markers can map spatial relationships between CCDC3-expressing cells and immune infiltrates

  • This approach can identify potential paracrine signaling networks involving CCDC3

• Flow cytometry applications:

  • Intracellular staining for CCDC3 in immune cell populations can identify which immune cells produce CCDC3

  • Cell sorting based on CCDC3 expression could isolate populations for functional characterization

• Neutralization studies:

  • Function-blocking antibodies against CCDC3 in co-culture systems containing immune and tumor cells can determine whether CCDC3 is necessary for observed immune responses

  • This approach could reveal whether CCDC3 acts as an immune checkpoint regulator

• Receptor identification:

  • Antibodies against CCDC3 can be used in receptor-ligand interaction screens to identify potential CCDC3 receptors on immune cells

  • Co-immunoprecipitation with CCDC3 antibodies followed by mass spectrometry could identify binding partners

Given that CIBERSORT analysis has already established correlations between CCDC3 expression and specific immune cell infiltration patterns , focused studies using these antibody-based approaches could elucidate the mechanistic basis for these correlations and potentially identify novel immunotherapeutic strategies.

What novel approaches could leverage CCDC3 antibodies for therapeutic development?

CCDC3 antibodies could facilitate therapeutic development through several innovative approaches:

• Bispecific antibody platforms:

  • Using the structural insights from bispecific antibody design , researchers could develop CCDC3xCD3 bispecific antibodies similar to other therapeutic bispecifics like BCMAxCD3

  • This approach could potentially recruit T cells to CCDC3-expressing tumors or adipose tissue

• Antibody-drug conjugates (ADCs):

  • Anti-CCDC3 antibodies conjugated to cytotoxic payloads could target cells producing high levels of CCDC3

  • This strategy might be particularly relevant for cancers with CCDC3 overexpression

• Functional modulation:

  • Antibodies that block or enhance CCDC3 function could modulate its biological activity

  • This approach requires deeper understanding of CCDC3's binding partners and signaling mechanisms

• Diagnostic applications:

  • CCDC3 antibodies could be developed into companion diagnostics to identify patients likely to benefit from CCDC3-targeted therapies

  • Quantitative assessment of CCDC3 levels might provide prognostic information

• Targeted delivery systems:

  • Nanoparticles or liposomes decorated with CCDC3 antibodies could deliver therapeutic payloads to CCDC3-rich microenvironments

  • This might be particularly relevant for targeting the adipose-tumor interface

These approaches would benefit from improved understanding of CCDC3 biology, particularly identification of its receptors and downstream signaling pathways, which could be facilitated by the various antibody-based research techniques discussed throughout this FAQ.

How can researchers optimize CCDC3 antibody-based approaches for studying adipose tissue-tumor interactions?

Optimizing antibody-based approaches for adipose tissue-tumor interactions requires addressing several technical and biological considerations:

• Tissue-specific sample preparation:

  • Adipose tissue presents unique challenges due to high lipid content

  • Modified extraction protocols using lipid-compatible detergents improve CCDC3 recovery

  • Centrifugation steps must be optimized to separate the lipid layer from the protein fraction

• 3D co-culture systems:

  • Traditional 2D cultures poorly recapitulate adipose-tumor interactions

  • 3D co-culture systems with adipocytes and tumor cells provide more physiologically relevant models

  • CCDC3 antibodies can be used for immunofluorescence in these systems, but require optimization for penetration and background reduction

• In vivo imaging approaches:

  • Fluorescently-labeled CCDC3 antibodies could track CCDC3 distribution in xenograft models

  • Near-infrared fluorophore conjugation enables deeper tissue penetration for imaging

  • Careful validation of antibody specificity in the complex in vivo environment is essential

• Ex vivo tissue analysis:

  • Fresh tissue explants maintain the complex architecture of tumor-adipose interfaces

  • Multiplex immunostaining with CCDC3 antibodies can map expression patterns relative to other markers

  • Laser capture microdissection can isolate specific regions for detailed molecular analysis

• Secretome analysis:

  • CCDC3 is a secreted protein that functions in the extracellular environment

  • Antibody-based enrichment of conditioned media from co-cultures can enhance detection of low-abundance secreted factors including CCDC3

  • Multiplex antibody arrays incorporating CCDC3 antibodies can profile the full adipose-tumor secretome

These optimized approaches would enable researchers to better understand how adipocyte-derived CCDC3 influences tumor behavior in its native context, potentially leading to novel therapeutic targets at the adipose-tumor interface.